Welcome to our dedicated page for ANAPTYSBIO SEC filings (Ticker: ANABV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANAPTYSBIO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANAPTYSBIO's regulatory disclosures and financial reporting.
ANAB (issuer) notice of proposed sale: the filing lists multiple planned dispositions of Common Stock by Dennis Mulroy via stock option exercises and cash settlements. The excerpt shows repeated sales dated from 05/15/2026 through 06/05/2026, with individual transactions such as 20,000 shares on 06/04/2026.
ANAB (issuer) notice of proposed sale: the filing lists multiple planned dispositions of Common Stock by Dennis Mulroy via stock option exercises and cash settlements. The excerpt shows repeated sales dated from 05/15/2026 through 06/05/2026, with individual transactions such as 20,000 shares on 06/04/2026.
ANAB reported a Form 144 registering 20,000 common shares for sale on 06/03/2026. The filing lists the sale method as Stock Option Exercise for 20,000 shares on 06/03/2026 for cash. The excerpt also records multiple sales by Dennis Mulroy during May–June 2026, including 15,000 shares on 05/29/2026 for $834,903.00 and other transactions totaling many tens of thousands of shares in the preceding weeks.
ANAB reported a Form 144 registering 20,000 common shares for sale on 06/03/2026. The filing lists the sale method as Stock Option Exercise for 20,000 shares on 06/03/2026 for cash. The excerpt also records multiple sales by Dennis Mulroy during May–June 2026, including 15,000 shares on 05/29/2026 for $834,903.00 and other transactions totaling many tens of thousands of shares in the preceding weeks.
ANAB affiliate filed a Form 144 proposing the sale of 20,000 shares of Common Stock via a Stock Option Exercise on 06/02/2026. The excerpt lists prior cash sales by Dennis Mulroy between 05/15/2026 and 06/01/2026, including individual sale amounts such as $928,071.04 for 15,467 shares on 05/21/2026.
ANAB affiliate filed a Form 144 proposing the sale of 20,000 shares of Common Stock via a Stock Option Exercise on 06/02/2026. The excerpt lists prior cash sales by Dennis Mulroy between 05/15/2026 and 06/01/2026, including individual sale amounts such as $928,071.04 for 15,467 shares on 05/21/2026.
ANAB affiliate reported a proposed resale of 7,691 shares. The filing states 06/01/2026 as the planned sale date and lists the transaction as a stock option exercise with proceeds in cash. The filing identifies Dennis Mulroy as the selling party and shows multiple recent dispositions in May 2026.
ANAB affiliate reported a proposed resale of 7,691 shares. The filing states 06/01/2026 as the planned sale date and lists the transaction as a stock option exercise with proceeds in cash. The filing identifies Dennis Mulroy as the selling party and shows multiple recent dispositions in May 2026.
AnaptysBio, Inc. is providing tax information to its stockholders about the dividend they received from the separation and spin-off of First Tracks Biotherapeutics, Inc. The company has filed IRS Form 8937 and is making the same information available in the Investors section of its website.
The Form 8937 explains how the spin-off dividend is treated for tax purposes and how stockholders should determine their adjusted tax basis. AnaptysBio emphasizes that this material is for informational purposes only and urges stockholders to consult their own tax advisors about their specific situations.
AnaptysBio, Inc. is providing tax information to its stockholders about the dividend they received from the separation and spin-off of First Tracks Biotherapeutics, Inc. The company has filed IRS Form 8937 and is making the same information available in the Investors section of its website.
The Form 8937 explains how the spin-off dividend is treated for tax purposes and how stockholders should determine their adjusted tax basis. AnaptysBio emphasizes that this material is for informational purposes only and urges stockholders to consult their own tax advisors about their specific situations.
ANAB filing under Rule 144 reports a proposed sale of 15,000 common shares via a stock option exercise on 05/29/2026. The filing lists multiple recent dispositions by Dennis Mulroy with trade dates and gross proceeds, including sales on 05/28/2026 (10,264 shares, $594,671.20) and earlier May sales.
ANAB filing under Rule 144 reports a proposed sale of 15,000 common shares via a stock option exercise on 05/29/2026. The filing lists multiple recent dispositions by Dennis Mulroy with trade dates and gross proceeds, including sales on 05/28/2026 (10,264 shares, $594,671.20) and earlier May sales.
ANAB — Form 144 filing reports planned and recent sales of common stock by Dennis Mulroy. The notice lists a stock option exercise on 05/28/2026 covering 10,264 shares to be sold for cash. The filing also itemizes recent sales totaling 75,467 shares across dates in May 2026 with reported gross proceeds per trade.
ANAB — Form 144 filing reports planned and recent sales of common stock by Dennis Mulroy. The notice lists a stock option exercise on 05/28/2026 covering 10,264 shares to be sold for cash. The filing also itemizes recent sales totaling 75,467 shares across dates in May 2026 with reported gross proceeds per trade.
Dennis Mulroy reported multiple proposed sales of Common Stock on a Form 144, including notices to sell 10,000 shares tied to a stock option exercise dated 05/27/2026. The excerpt lists several recent dispositions dated 05/15/2026–05/26/2026 with gross proceeds shown for each sale.
Dennis Mulroy reported multiple proposed sales of Common Stock on a Form 144, including notices to sell 10,000 shares tied to a stock option exercise dated 05/27/2026. The excerpt lists several recent dispositions dated 05/15/2026–05/26/2026 with gross proceeds shown for each sale.
An affiliate filing to sell shares via Form 144. The filing lists a stock option exercise for 10,000 shares dated 05/26/2026 to be sold for cash. The excerpt also reports multiple recent dispositions by Dennis Mulroy on 05/22/2026, 05/21/2026, 05/19/2026, and 05/15/2026 with specific share counts and gross proceeds.
An affiliate filing to sell shares via Form 144. The filing lists a stock option exercise for 10,000 shares dated 05/26/2026 to be sold for cash. The excerpt also reports multiple recent dispositions by Dennis Mulroy on 05/22/2026, 05/21/2026, 05/19/2026, and 05/15/2026 with specific share counts and gross proceeds.
ANAB affiliate files a proposed sale of 10,000 shares. The filing notifies a stock option exercise sale of 10,000 shares on 05/22/2026 for cash. The filing also lists recent sales by the reporting person: 15,467 shares on 05/21/2026 for $928,071.04, 10,000 shares on 05/19/2026 for $599,000.00, and 10,000 shares on 05/15/2026 for $632,543.00.
ANAB affiliate files a proposed sale of 10,000 shares. The filing notifies a stock option exercise sale of 10,000 shares on 05/22/2026 for cash. The filing also lists recent sales by the reporting person: 15,467 shares on 05/21/2026 for $928,071.04, 10,000 shares on 05/19/2026 for $599,000.00, and 10,000 shares on 05/15/2026 for $632,543.00.